Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2023

09.11.2022 | Original Article

Comparative evaluation of radionuclide therapy using 90Y and 177Lu

verfasst von: Hirofumi Hanaoka, Kazuyuki Hashimoto, Satoshi Watanabe, Shojiro Matsumoto, Tetsuya Sakashita, Shigeki Watanabe, Noriko S. Ishioka, Keigo Endo

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Both 90Y and 177Lu are attractive β-emitters for radionuclide therapy and have been used in clinical practice. Nevertheless, comparative evaluation between 90Y- and 177Lu-labeled molecules has not been fully conducted. Thus, in this study, the features of 90Y and 177Lu for radionuclide therapy were assessed in tumor-bearing mice.

Methods

Two tumor cell lines with different growth rates were used. Biodistribution studies of 177Lu-labeled antibodies (177Lu-Abs) were conducted in each tumor-bearing mouse model. Subsequently, the therapeutic effect of 90Y- and 177Lu-Ab were assessed in tumor-bearing mice. The absorbed radiation dose for the tumor was estimated using the Monte Carlo simulation.

Results

177Lu-Abs demonstrated high tumor accumulation in both tumor-xerograph. In the fast-growing tumor model, 90Y-Ab showed a better therapeutic effect than 177Lu-Ab, reflecting a higher absorbed radiation dose of 90Y-Ab than that of 177Lu-Ab. In the slow-growing tumor model, both 90Y- and 177Lu-Ab showed an excellent therapeutic effect; however, 177Lu-Ab had a longer efficacy period than 90Y-Ab, which could be attributed to the longer half-life and better dose uniformity of 177Lu than those of 90Y.

Conclusions

To accomplish a maximum therapeutic effect, selecting 90Y or 177Lu, to depend on the growth rate of individual cancer, would be helpful.
Literatur
1.
Zurück zum Zitat Read ED, Eu P, Little PJ, Piva TJ. The status of radioimmunotherapy in CD20 + non-Hodgkin’s lymphoma. Target Oncol. 2015;10:15–26. CrossRef Read ED, Eu P, Little PJ, Piva TJ. The status of radioimmunotherapy in CD20 + non-Hodgkin’s lymphoma. Target Oncol. 2015;10:15–26. CrossRef
2.
Zurück zum Zitat Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–60. CrossRef Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–60. CrossRef
3.
Zurück zum Zitat Hope TA, Pavel M, Bergsland EK. Neuroendocrine tumors and peptide receptor radionuclide therapy: when is the right time? J Clin Oncol. 2022;40:2818–29. CrossRef Hope TA, Pavel M, Bergsland EK. Neuroendocrine tumors and peptide receptor radionuclide therapy: when is the right time? J Clin Oncol. 2022;40:2818–29. CrossRef
4.
Zurück zum Zitat Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:67S-76S. CrossRef Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:67S-76S. CrossRef
5.
Zurück zum Zitat Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, et al. Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies. Cancers (Basel). 2021;14:129. CrossRef Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, et al. Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies. Cancers (Basel). 2021;14:129. CrossRef
6.
Zurück zum Zitat Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9:16932–50. CrossRef Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9:16932–50. CrossRef
7.
Zurück zum Zitat Rathke H, Flechsig P, Mier W, Bronzel M, Mavriopoulou E, Hohenfellner M, et al. Dosimetry estimate and initial clinical experience with 90Y-PSMA-617. J Nucl Med. 2019;60:806–11. CrossRef Rathke H, Flechsig P, Mier W, Bronzel M, Mavriopoulou E, Hohenfellner M, et al. Dosimetry estimate and initial clinical experience with 90Y-PSMA-617. J Nucl Med. 2019;60:806–11. CrossRef
8.
Zurück zum Zitat Nguyen-Thu H, Hanaoka H, Nakajima T, Yamaguchi A, Nguyen-Cong T, Kartamihardja AAP, et al. Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18F-FDG-PET. Breast Cancer. 2018;25:334–42. CrossRef Nguyen-Thu H, Hanaoka H, Nakajima T, Yamaguchi A, Nguyen-Cong T, Kartamihardja AAP, et al. Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18F-FDG-PET. Breast Cancer. 2018;25:334–42. CrossRef
9.
Zurück zum Zitat Watanabe S, Hashimoto K, Watanabe S, Iida Y, Hanaoka H, Endo K, et al. Production of highly purified no-carrier-added 177Lu for radioimmunotherapy. J Radioanal Nucl Chem. 2015;303:935–40. CrossRef Watanabe S, Hashimoto K, Watanabe S, Iida Y, Hanaoka H, Endo K, et al. Production of highly purified no-carrier-added 177Lu for radioimmunotherapy. J Radioanal Nucl Chem. 2015;303:935–40. CrossRef
10.
Zurück zum Zitat Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, et al. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of 177Lu and comparison of its efficacy with that of 90Y and residualizing 131I. J Nucl Med. 2001;42:967–74. Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, et al. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of 177Lu and comparison of its efficacy with that of 90Y and residualizing 131I. J Nucl Med. 2001;42:967–74.
11.
Zurück zum Zitat Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, et al. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898–906. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, et al. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898–906.
12.
Zurück zum Zitat Heryanto YD, Hanaoka H, Nakajima T, Yamaguchi A, Tsushima Y. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts. Ann Nucl Med. 2017;31:669–77. CrossRef Heryanto YD, Hanaoka H, Nakajima T, Yamaguchi A, Tsushima Y. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts. Ann Nucl Med. 2017;31:669–77. CrossRef
13.
Zurück zum Zitat Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327–37. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327–37.
14.
Zurück zum Zitat Yudistiro R, Hanaoka H, Katsumata N, Yamaguchi A, Tsushima Y. Bevacizumab radioimmunotherapy (RIT) with accelerated blood clearance using the avidin chase. Mol Pharm. 2018;15:2165–73. CrossRef Yudistiro R, Hanaoka H, Katsumata N, Yamaguchi A, Tsushima Y. Bevacizumab radioimmunotherapy (RIT) with accelerated blood clearance using the avidin chase. Mol Pharm. 2018;15:2165–73. CrossRef
15.
Zurück zum Zitat Sakashita T, Watanabe S, Hanaoka H, Ohshima Y, Ikoma Y, Ukon N, et al. Absorbed dose simulation of meta- 211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method. RAP Ann Nucl Med. 2021;35:121–31. CrossRef Sakashita T, Watanabe S, Hanaoka H, Ohshima Y, Ikoma Y, Ukon N, et al. Absorbed dose simulation of meta- 211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method. RAP Ann Nucl Med. 2021;35:121–31. CrossRef
16.
Zurück zum Zitat Peer-Firozjaei M, Tajik-Mansoury MA, Ghorbani R, Mazinani M. Evaluation of dosimetric parameters for tumor therapy with 177Lu and 90Y radionuclides in gate Monte Carlo code. J Biomed Phys Eng. 2021;11:263–70. Peer-Firozjaei M, Tajik-Mansoury MA, Ghorbani R, Mazinani M. Evaluation of dosimetric parameters for tumor therapy with 177Lu and 90Y radionuclides in gate Monte Carlo code. J Biomed Phys Eng. 2021;11:263–70.
17.
Zurück zum Zitat Shiiba T, Kuga N, Kuroiwa Y, Sato T. Evaluation of the accuracy of mono-energetic electron and beta-emitting isotope dose-point kernels using particle and heavy ion transport code system: PHITS. App Radiat Isot. 2017;128:199–203. CrossRef Shiiba T, Kuga N, Kuroiwa Y, Sato T. Evaluation of the accuracy of mono-energetic electron and beta-emitting isotope dose-point kernels using particle and heavy ion transport code system: PHITS. App Radiat Isot. 2017;128:199–203. CrossRef
18.
Zurück zum Zitat Hanaoka H, Kuroki M, Yamaguchi A, Achmad A, Iida Y, Higuchi T, et al. Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody. Cancer Biother Radiopharm. 2014;29:70–6. Hanaoka H, Kuroki M, Yamaguchi A, Achmad A, Iida Y, Higuchi T, et al. Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody. Cancer Biother Radiopharm. 2014;29:70–6.
19.
Zurück zum Zitat O’Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–9. O’Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–9.
20.
Zurück zum Zitat Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome Med. 2021;13:120. CrossRef Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome Med. 2021;13:120. CrossRef
21.
Zurück zum Zitat Xiao Y, Shen J, Zou X. Mathematical modeling and dynamical analysis of anti-tumor drug dose–response. Math Biosci Eng. 2022;19:4120–44. CrossRef Xiao Y, Shen J, Zou X. Mathematical modeling and dynamical analysis of anti-tumor drug dose–response. Math Biosci Eng. 2022;19:4120–44. CrossRef
22.
Zurück zum Zitat Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7. CrossRef Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7. CrossRef
23.
Zurück zum Zitat Severi S, Bongiovanni A, Ferrara M, Nicolini S, Di Mauro F, Sansovini M, et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open. 2021;6: 100171. CrossRef Severi S, Bongiovanni A, Ferrara M, Nicolini S, Di Mauro F, Sansovini M, et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open. 2021;6: 100171. CrossRef
24.
Zurück zum Zitat Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/ 177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97. CrossRef Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/ 177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97. CrossRef
Metadaten
Titel
Comparative evaluation of radionuclide therapy using 90Y and 177Lu
verfasst von
Hirofumi Hanaoka
Kazuyuki Hashimoto
Satoshi Watanabe
Shojiro Matsumoto
Tetsuya Sakashita
Shigeki Watanabe
Noriko S. Ishioka
Keigo Endo
Publikationsdatum
09.11.2022
Verlag
Springer Nature Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2023
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01803-y

Weitere Artikel der Ausgabe 1/2023

Annals of Nuclear Medicine 1/2023 Zur Ausgabe